Despite the frequent co-occurrence of EoE with other allergic diseases and the ability of dietary antigen removal to resolve inflammation15, immunoglobulin E (IgE) appeared dispensable in an animal model of TSLP-dependent EoE12, and anti-IgE therapy (omalizumab) failed to improve symptoms or decrease esophageal eosinophilia in a human trial16. This evidence concerns the gene IGHE and eosinophilic esophagitis.